Acquisition of Israel-based company, known for its innovative regeneration products with the clinically superior proprietary technology GLYMATRIX®, complements Dentsply Sirona’s existing implant dentistry strategy.
The acquisition of Datum Dental will open up significant opportunities for Dentsply Sirona within its Implants segment. With a track record of simplifying and developing innovations for regenerative procedures, the OSSIX® portfolio will support the vision to become one of the leaders in the dental regeneration industry.
With innovative products driven by the GLYMATRIX®core technology, OSSIX bio-durable design will ensure long-term predictable and superior results. The OSSIX dental regeneration products will support and enhance the future of implant dentistry and oral care.
The biomaterial sector is an important cornerstone of the future of dentistry, according to Dentsply Sirona, and this acquisition is another important step to deliver on the company’s purpose to empower dental professionals to provide patients with better dental care and make people smile, according to Gene Dorff, Group Vice President Implants Product Group of Dentsply Sirona.
Since 2016, Dentsply Sirona has already been in distribution agreements with Datum Dental. Today, Dentsply Sirona is promoting the full OSSIX portfolio (OSSIX®Plus, OSSIX® Volumax, and OSSIX™ Bone) in the U.S., Canada, Colombia, France, Belgium, UK-Ireland, Nordics, Poland, Romania, Turkey and Hong Kong.
Clinicians will benefit in the future from OSSIX products’ being implemented in a broad set of solutions and workflows and Dentsply Sirona’s capacity to invest in the future development, the companies state. The strong OSSIX portfolio will be the foundation of the Regenerative portfolio of Dentsply Sirona. The transaction is expected to close in January 2021, following customary approval requirements.